AMGEN at Neulasta
BACK TO MARKETED PRODUCTS

Can the method
you choose for
G-CSF delivery
make a clinical
difference?

FIND OUT HERE

G-CSF = granulocyte colony-stimulating factor.

Neulasta® Onpro® is the #1 prescribed long-acting G-CSF
and has been prescribed to over 1 million patients1,2

How Your Choice of G-CSF Delivery Method Matters

In the pivotal trial, next-day Neulasta® (pegfilgrastim) reduced the incidence of febrile neutropenia (FN) and FN-related hospitalizations when used every cycle, at the right time3,*

REDUCED THE
INCIDENCE OF FN BY

94%

Neulasta® 1% vs placebo
17%, P < 0.001

REDUCED FN-RELATED
HOSPITALIZATION BY

93%

Neulasta® 1% vs placebo
14%, P < 0.001

*

Do not administer Neulasta® between 14 days before and 24 hours after administration of cytotoxic chemotherapy.

Pivotal trial study design and results3

Phase 3, multicenter, multinational, double-blind, placebo-controlled trial of patients with breast cancer (Neulasta® [n = 463] or placebo [n = 465]) receiving 100 mg/m2 docetaxel Q3W for up to 4 cycles. The key endpoint was the percentage of patients who developed FN (Neulasta® 1% versus placebo 17%, P < 0.001). Also, secondary endpoints were lower for Neulasta®-treated patients as compared to placebo-treated patients (the incidence of hospitalization [1% versus 14%] and IV anti-infective use [2% versus 10%]).

FN = temperature ≥ 38.2°C and absolute neutrophil count (ANC) < 0.5 x 109/L.

Q3W = once every 3 weeks, IV = intravenous.

In a prospective observational study of ~2600 cancer patients

Patients who received Neulasta® Onpro® had a lower frequency of FN vs other
FN-prophylaxis options4,5

Patient Group Relative decrease
in FN for Onpro®*		 % of patients with
FN [95% CI]		 N
Other FN-prophylaxis options

36%

 9.4%
[7.51% - 11.21%] 		951
Neulasta® Onpro® (all cycles) 6.2%
[4.95% - 7.42%] 		1455
Other FN-prophylaxis options

33%

 9.4%
[7.51% - 11.21%] 		951
Neulasta® Onpro® (1st cycle) 6.4%
[5.21% - 7.59%] 		1624

See study
design and
limitations below.

This was an observational study and no formal statistical testing was performed. Descriptive statistics are available.

*

Adjusted for baseline clinical and demographic differences between the groups, eg, degree of FN risk of chemotherapy regimen.

The primary endpoint was the overall incidence of FN over four cycles of chemotherapy, measured as ANC < 1000 × 106/L and one of the following occurring within 24 hours of decreased ANC: Temperature > 38°C, use of specific oral antibiotics (eg, ciprofloxacin, levofloxacin, moxifloxacin, amoxicillin-clavulanate), or use of IV antibiotics.5

CI = confidence interval.

A lower frequency of FN was shown by using Onpro® every cycle, at the right time

More patients received G-CSF support across every cycle with Neulasta® Onpro®5

94% of patients who received Neulasta® Onpro® in the first cycle received a G-CSF across all cycles of chemotherapy.

More patients received G-CSF support at the right time with Neulasta® Onpro®5

95.5% of patients receiving Neulasta® Onpro® in every cycle received it on the day after chemotherapy.

*

Percent of patients receiving pegfilgrastim PFS (innovator or biosimilar) on the day after chemotherapy, for all cycles in which pegfilgrastim PFS was administered.

Note: For any given patient, physicians generally chose the same FN-prevention therapy over time. However, a small percentage of patients received different therapies in different cycles. To facilitate comparison, the Onpro® group was comprised of patients who received Onpro® in every cycle. The comparator group was comprised of patients in the other physician-choice group who received pegfilgrastim PFS (innovator or biosimilar) at least once, and measured patient compliance for only those cycles in which pegfilgrastim PFS was administered.

PFS = prefilled syringe.

9 out of 10 patients who received Neulasta® Onpro® in the first cycle received Onpro® in every cycle

Study Design4,5
  • Prospective, observational US study to describe frequency of FN, adherence, and compliance among patients receiving myelosuppressive chemotherapy for breast, lung, prostate, or NHL malignancies
  • The study enrolled patients from November 2018 to April 2020
  • The primary analysis included 2575 patients who completed up to four chemotherapy cycles
  • Investigators decided on the method of FN-prophylaxis. Patients were grouped into either the Neulasta® Onpro® group or other FN-prophylaxis group based on FN-prophylaxis method received in the first cycle. In both groups, physicians could change the type of G-CSF used in the following cycles (choice in first cycle was generally consistent across subsequent cycles)
    • Other FN-prophylaxis options included Neulasta® PFS or pegfilgrastim biosimilar PFS (61.7%), daily short-acting filgrastim or filgrastim biosimilar (7.3%), or no G-CSF (30.9%)
  • Secondary endpoints included: 1) Patients who received G-CSF support for all chemotherapy cycles regardless of timing of G-CSF administration (persistence) and
    2) Patients who received pegfilgrastim on the day after chemotherapy in every cycle in which pegfilgrastim was administered (compliance)
Study Limitations5
  • It was not possible to evaluate FN risk among patients lost to follow-up after study enrollment
  • Although the analysis of FN incidence controlled for known baseline differences between the groups, the lack of randomization means that the groups may have differed in ways that were not measured or recorded. The impact of such differences on the study findings is unknown
  • The study enrollment closed prematurely due to COVID-19 and did not achieve target sample sizes

NHL = non-Hodgkin’s lymphoma.

Maintaining Your Patients' Treatment Plan

Real-world study of cancer patients undergoing chemotherapy

Next-day Neulasta® helped significantly more patients to maintain their chemotherapy dosing and schedule

Percent Who Maintained Relative
Dose Intensity (RDI)6
Next-day Neulasta® reduces risk of FN and helped significantly more patients maintain RDI.3,6

98%

Odds Ratio = 1.98

Unadjusted for clinical and demographic characteristics, 98% more likely to maintain RDI over the course of chemotherapy vs no G-CSF6,*,†

Note: The odds ratio is the relationship of the next-day Neulasta® group’s odds to the No G-CSF group’s odds of maintaining RDI.

Note: The odds ratio is the relationship of the next-day Neulasta® group’s odds to the No G-CSF group’s odds of maintaining RDI.

48%

Odds Ratio = 1.48,
P = 0.006‡

Adjusted for clinical and demographic characteristics, 48% more likely to maintain RDI over the course of chemotherapy vs no G-CSF6,*,†

Study Design: Retrospective cohort study conducted at Geisinger Health System (Danville, PA), Henry Ford Health System (Detroit, MI), Kaiser Permanente Northwest (Portland, OR), and Reliant Medical Group (Worcester, MA), January 2009-December 2017 (for all sites except Geisinger, 2009-2014). Analysis included patients with breast cancer, colorectal cancer, lung cancer, or non-Hodgkin’s lymphoma, receiving chemotherapy regimens with high or intermediate risk of FN. Multivariable regression models were employed to estimate the relationship between the use of Neulasta® and RDI.

Dose intensity is defined as the delivered dose of chemotherapy per unit of time. Relative dose intensity (RDI) is expressed as a percentage, calculated as the delivered dose intensity divided by the standard dose intensity. A higher RDI is indicative of fewer dose reductions and delays. Patients with RDI ≥ 85% were considered to have maintained their dose. The 85% cut point is commonly reported in the literature.7

It was not possible to determine from the data whether patients received Onpro® or the prefilled syringe. However, of the 379 patients from these healthcare systems who received Neulasta® in the first cycle, 97% (n = 368) received it on the day following chemotherapy, as recommended in the Neulasta® Prescribing Information. The Neulasta® group in this analysis was limited to next-day patients.

*

RDI ≥ 85%.

†

Course-level analysis. All cycles included. The analysis categorized patients as next-day Neulasta® users vs non-users of G-CSF based on the first cycle of chemotherapy only. However, for patients who received next-day Neulasta® in cycle 1, subsequent Neulasta® use was: 87% in cycle 2, 86% in cycle 3, and 78% in cycle 4. For patients who did not receive any G-CSF in cycle 1, no G-CSF use was 81% in cycle 2, 79% in cycle 3, and 79% in cycle 4.

‡

Adjusted odds ratio controlling for clinical and demographic characteristics, including but not limited to age, metastasis (yes/no), and FN risk of chemotherapy regimen.

What Patients and Nurses Say

Neulasta® Onpro® is patient- and nurse-chosen protection*

95%

95% of patients and nurses would choose Neulasta® Onpro® again8,9,†,‡

  • Not having to return to the doctor’s office the day after chemotherapy just for an injection was the most important factor for patients when choosing a G-CSF9,§
  • Patients also valued how much experience their doctor has with the G-CSF they would receive and being informed by the doctor or nurse of all available ways to receive the G-CSF9
*

In a key study of 928 patients with breast cancer, when given once every chemotherapy cycle, 17% of patients got infections when not treated with Neulasta®—while only 1% of patients got infections when treated with Neulasta®.3

†

2016 data from interviews with oncology patients who have had experience with Neulasta® ([N = 227], PFS [n = 150], Neulasta® Onpro® [n = 77]).9

‡

Data from interviews with oncology nurses (N = 250) conducted in October 2016. Respondents were asked if they agree with this statement: Based on my Neulasta® Onpro® experience, when my patients are appropriate for Neulasta® (PFS or Neulasta® Onpro®), I would choose Neulasta® Onpro®.8

§

November 2016 data from interviews with oncology patients who have had experience with Neulasta® ([N = 227], PFS [n = 150], Neulasta® Onpro® [n = 77]). Patients were asked a multiple-choice selection prompt.9

Neulasta® Onpro® is the #1 prescribed long-acting G-CSF and has been prescribed to over 1 million patients1,2

Every patient has a story about how Neulasta® Onpro® makes a difference to them, as they tell us in their own words
Erica’s Story
" Sticking to my plan is the most important thing to me, and now my oncologist and I have a plan to do that with Neulasta® Onpro®—while also staying home to make memories with my daughter."
Shaquita’s Story
" The best part of using Neulasta® Onpro® is that I get the medication I need, while also protecting myself from other risks—at the hospital, doctor's office, etc—that would cause a delay in my chemotherapy."
Tara’s Story
"I knew from the day I walked out of the hospital that everybody was looking out for my best interest. Going home with Neulasta® Onpro® on my arm was like a shield of protection!"

Incomplete doses have been reported with Neulasta® Onpro® due to device not performing as intended. This may increase risk of neutropenia, febrile neutropenia, and/or infection.

Resources For You and Your Patients

Patient Brochure

Neulasta® Onpro® Prospective
Study Brochure

G-CSF Evolution
Flashcard

Assess your patient’s
risk of FN

Neulasta® Onpro®
RDI Brochure

RDI = Relative Dose Intensity.

References
  1. Data on file, Amgen; [1]; 2020.
  2. Data on file, Amgen; [2]; 2020.
  3. Vogel CL, et al. J Clin Oncol. 2005;23(6):1178-1184.
  4. Data on file, Amgen; [3]; 2020.
  5. Mahtani RL, et al. A multicenter, prospective, observational study to determine the incidence of febrile neutropenia (FN), persistence and G-CSF utilization among cancer patients at high risk for FN receiving pegfilgrastim by an on-body injector (OBI) versus other FN-prophylaxis strategies. Poster presented at: San Antonio Breast Cancer Symposium®, Virtual.
  6. Data on file, Amgen; [4]; 2020.
  7. Lyman GH. J Natl Compr Canc Netw. 2009;7:2612-2615.
  8. Data on file, Amgen; 2016.
  9. Data on file, Amgen; [5]; 2020.
IMPORTANT SAFETY INFORMATION AND INDICATION
See More

Important safety information
Contraindication • Neulasta® is contraindicated in patients with a history of serious allergic reactions to pegfilgrastim or filgrastim • Reactions have included anaphylaxis Splenic Rupture • Splenic rupture, including fatal cases, can occur following the administration of Neulasta®• Evaluate for an enlarged or ruptured spleen in patients who report left upper abdominal or shoulder pain Acute Respiratory Distress Syndrome (ARDS) • ARDS has occurred in patients receiving Neulasta® • Evaluate patients who develop a fever and lung infiltrates or respiratory distress after receiving Neulasta® • Discontinue Neulasta® in patients with ARDS Serious Allergic Reactions • Serious allergic reactions, including anaphylaxis can occur in patients receiving Neulasta®

INDICATION

Neulasta® is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti‑cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Neulasta® is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Important safety information

Contraindication
  • Neulasta® is contraindicated in patients with a history of serious allergic reactions to pegfilgrastim or filgrastim
  • Reactions have included anaphylaxis
Splenic Rupture
  • Splenic rupture, including fatal cases, can occur following the administration of Neulasta®
  • Evaluate for an enlarged or ruptured spleen in patients who report left upper abdominal or shoulder pain
Acute Respiratory Distress Syndrome (ARDS)
  • ARDS has occurred in patients receiving Neulasta®
  • Evaluate patients who develop a fever and lung infiltrates or respiratory distress after receiving Neulasta®
  • Discontinue Neulasta® in patients with ARDS
Serious Allergic Reactions
  • Serious allergic reactions, including anaphylaxis can occur in patients receiving Neulasta®
  • Majority of events occurred upon initial exposure and can recur within days after discontinuation of initial anti-allergic treatment
  • Permanently discontinue Neulasta® in patients with serious allergic reactions
Allergies to Acrylics
  • On-body injector (OBI) for Neulasta® uses acrylic adhesives
  • Patients who are allergic to acrylic adhesives may have a significant reaction
Use in Patients With Sickle Cell Disorders
  • In patients with sickle cell trait or disease, severe and sometimes fatal sickle cell crises can occur in patients receiving Neulasta®
  • Discontinue Neulasta® if sickle cell crisis occurs
Glomerulonephritis
  • Has occurred in patients receiving Neulasta®
  • Diagnoses based on azotemia, hematuria, proteinuria, and renal biopsy
  • Generally events resolved after dose reduction or discontinuation of Neulasta®
  • If suspected, evaluate for cause and if cause is likely, consider dose-reduction or interruption of Neulasta®
Leukocytosis
  • Increased white blood cell counts of 100 x 109/L have been observed
  • Monitoring of complete blood count (CBC) during pegfilgrastim therapy is recommended
Thrombocytopenia
  • Thrombocytopenia has been reported in patients receiving pegfilgrastim. Monitor platelet counts
Capillary Leak Syndrome (CLS)
  • CLS has been reported after G-CSF administration, including Neulasta®
  • Characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration
  • Episodes vary in frequency, severity, and may be life-threatening if treatment is delayed
  • Patients with symptoms should be closely monitored and receive standard symptomatic treatment, which may include intensive care
Potential for Tumor Growth Stimulatory Effects on Malignant Cells
  • G-CSF receptor has been found on tumor cell lines
  • The possibility that pegfilgrastim acts as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which Neulasta® is not approved, cannot be excluded
Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) in Patients With Breast and Lung Cancer
  • MDS and AML have been associated with the use of Neulasta® in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer. Monitor patients for signs and symptoms of MDS/AML in these settings
Potential Device Failures
  • Missed or partial doses have been reported in patients receiving pegfilgrastim via the on-body injector (OBI) due to the device not performing as intended
  • In the event of a missed or partial dose, patients may be at increased risk of events such as neutropenia, febrile neutropenia and/or infection than if the dose had been correctly delivered
  • Instruct patients to notify their healthcare professional immediately in order to determine the need for a replacement dose if they suspect that the device may not have performed as intended
Aortitis
  • Aortitis has been reported in patients receiving Neulasta®. It may occur as early as the first week after start of therapy
  • Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (e.g., c-reactive protein and white blood cell count)
  • Consider aortitis in patients who develop these signs and symptoms without known etiology. Discontinue Neulasta® if aortitis is suspected
Nuclear Imaging
  • Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes. This should be considered when interpreting bone imaging results
Most common adverse reactions
  • Bone pain
  • Pain in extremity

Please see Neulasta® full Prescribing Information.

Neulasta® Injection: 6 mg/0.6 mL in a single-dose prefilled syringe for manual use only. Neulasta® Injection: 6 mg/0.6 mL in a single-dose prefilled syringe co-packaged with the on-body injector (OBI) for Neulasta® (Neulasta® Onpro® kit).

Special Instructions for the On‐body Injector (OBI) for Neulasta®

A healthcare provider must fill the on-body injector (OBI) with Neulasta® using the co-packaged prefilled syringe and then apply the OBI to the patient’s skin (abdomen or back of arm). The back of the arm may only be used if there is a caregiver available to monitor the status of the OBI. Approximately 27 hours after the OBI is applied to the patient’s skin, Neulasta® will be delivered over approximately 45 minutes. A healthcare provider may initiate administration with the OBI on the same day as the administration of cytotoxic chemotherapy, as long as the OBI delivers Neulasta® no less than 24 hours after the administration of cytotoxic chemotherapy.

The prefilled syringe co-packaged in the Neulasta® Onpro® kit contains additional solution to compensate for liquid loss during delivery through the OBI. If this syringe is used for manual subcutaneous injection, the patient will receive an overdose. If the prefilled syringe for manual use is used with the OBI, the patient may receive less than the recommended dose.

Do not use the OBI to deliver any other drug product except the Neulasta® prefilled syringe co-packaged with the OBI. Use of the OBI has not been studied in pediatric patients.

The OBI should be applied to intact, non-irritated skin on the arm or abdomen.

A missed dose could occur due to an OBI failure or leakage. Instruct patients using the OBI to notify their healthcare professional immediately in order to determine the need for a replacement dose of pegfilgrastim if they suspect that the device may not have performed as intended. If the patient misses a dose, a new dose should be administered by single prefilled syringe for manual use as soon as possible after detection.

Review the Patient Information and Patient Instructions for Use with the patient and provide the instructions to the patient.

Refer to the Healthcare Provider Instructions for Use for the OBI for full administration information.

For any OBI problems, call Amgen at 1-800-772-6436 or 1-844-MYNEULASTA (1-844-696-3852).